Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.19.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Revenues $ 527 $ 78 $ 1,223 $ 353
Operating expenses:        
Research and development (related party of $217, $227, $761 and $600), net of grant income of $0, $0, $37 and $44 1,453 966 3,850 2,944
General and administrative (related party of $288, $186, $860 and $573) 2,844 2,605 9,108 7,690
Total operating expenses 4,297 3,571 12,958 10,634
Operating loss (3,770) (3,493) (11,735) (10,281)
Other income (expense):        
Interest expense (related party of $474, $478, $1,426 and $1,437) (474) (478) (1,426) (1,437)
Interest income 20 4 64 13
Royalty income 0 4 4 15
Total other income (expense) (454) (470) (1,358) (1,409)
Consolidated net loss (4,224) (3,963) (13,093) (11,690)
Net loss attributable to noncontrolling interest 1 1 3 3
Net loss attributable to iBio, Inc. (4,223) (3,962) (13,090) (11,687)
Preferred stock dividends (64) (64) (195) (195)
Net loss available to iBio, Inc. (4,287) (4,026) (13,285) (11,882)
Comprehensive loss:        
Consolidated net loss (4,224) (3,963) (13,093) (11,690)
Other comprehensive income - foreign currency translation adjustments 0 0 0 0
Comprehensive loss $ (4,224) $ (3,963) $ (13,093) $ (11,690)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.22) $ (0.35) $ (0.71) $ (1.16)
Weighted-average common shares outstanding - basic and diluted 19,224 11,545 18,597 10,247